Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The continuous renal replacement therapy market is expected to increase from US$ 1,214.6 billion in 2023 to US$ 2,771.6 billion in 2033. The market is likely to capture an 8.6% CAGR during the forecast period.
Market Technological Advances to Improve Kidney Disease Management
Technological advancements in CRRT informed RRT dose and the application of sophisticated modalities have accelerated the treatment of AKI in critically sick patients. Such breakthroughs have significantly enlarged the field of extracorporeal therapy in the ICU. Furthermore, software integration is anticipated to become a new tool for enhanced equipment. Allowing CRRT treatments to be performed more efficiently and safely.
Integrating bioimpedance with online hematocrit data has an impact on therapy delivery and online hemodynamic stability. The incorporation of thermal energy balance aid in the monitoring of the patient's blood temperature. This enables a precise energy balance to be accomplished by changing the dialysate based on temperature sensors installed on blood and dialysate lines.
Integrated care is supported by technology such as data collecting, personalized advice delivery, and outcome measurement. As a result, implementing innovative software solutions aid in the treatment of acute renal injury and organ failure in critically ill patients.
Report Attribute | Details |
---|---|
Continuous Renal Replacement Therapy Market Value (2023) | US$ 1,214.6 billion |
Continuous Renal Replacement Therapy Market Anticipated Value (2033) | US$ 2,771.6 billion |
Continuous Renal Replacement Therapy Market Growth Rate (2023 to 2033) | 8.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The continuous renal replacement therapy market accounted for US$ 1,127.0 billion in 2022, expanding at an 8.3% CAGR from 2018 to 2022.
Continuous renal replacement therapy (CRRT) is a prominent treatment option for critically ill patients with acute kidney injury (AKI). Particularly in hemodynamically unstable individuals. It includes the removal of solutes from blood using hemodialysis, hemofiltration, or a combination of the two procedures. CRRT therapy is often administered in an ICU for roughly 24 hours, as opposed to other types of traditional renal replacement therapies. Such as intermittent hemodialysis (IHD), which is administered for 4 to 6 hours or less.
Leading acute treatment manufacturers are implementing crucial methods such as technical progress to improve dialysis care. For example, in 2019, Baxter International Inc. cleared their Pris Max system and integrated Ther Max blood warmer for continuous renal replacement therapy and therapeutic plasma exchange (TPE). Factors such as the increasing prevalence of acute renal injury worldwide, the rising incidence of sepsis, and ICU patients enhance the market.
Historical CAGR (2018 to 2022) | 8.3% |
---|---|
Forecast CAGR (2023 to 2033) | 8.6% |
As per the FMI analysts, a valuation of US$ 2,771.6 billion by 2033 end is estimated for the market.
2016 | US$ 681.75 billion |
---|---|
2021 | US$ 1,029.85 billion |
2022 | US$ 1,127.0 billion |
2023 | US$ 1,214.6 billion |
2033 | US$ 2,771.6 billion |
Continuous Renal Replacement Therapy Market:
Differentiating Aspects | Continuous Renal Replacement Therapy Market |
---|---|
Anticipated CAGR (2023 to 2033) | 8.6% |
Market Valuation (2023) | US$ 1,214.6 billion |
Growth Factors | The prevalence of chronic kidney disease has increased, which is driving diabetes, hypertension, and cardiovascular disease. |
Future Opportunities | Diabetes and hypertension are becoming more common. Increasing the risk of suffering acute kidney injury (AKI), and fueling the demand for continuous renal replacement treatment. |
Market Trends | The clinical advantages of continuous renal replacement therapy over intermittent blood purifying procedures be a key factor affecting the growth of the market for continuous renal replacement therapy. |
Hormone Replacement Therapy Market:
Differentiating Aspects | Hormone Replacement Therapy Market |
---|---|
Anticipated CAGR (2023 to 2033) | 6.3% |
Market Valuation (2023) | US$ 16.01 billion |
Growth Factors | Certain elements influencing the growth of the hormone replacement treatment (HRT) market include increased awareness of postmenopausal concerns among women. Moreover, an increase in drug research with novel delivery technologies, and hormonal imbalance disorders with an aging population. |
Future Opportunities | Increased unmet demands for hormone replacement in emerging nations. As well as increased awareness about the treatment of hormone diseases, drive pharmaceutical companies to launch new advanced medications in the worldwide market. |
Market Trends | Growing research and development initiatives by key companies for the discovery of novel therapies to treat hormonal imbalances. As well as increased product approvals are projected to aid in market expansion. |
Kidney Injury Treatment Market:
Differentiating Aspects | Kidney Injury Treatment Market |
---|---|
Anticipated CAGR (2023 to 2033) | 8.2% |
Market Valuation (2023) | US$ 2,052 million |
Growth Factors | Increased availability of dialysis therapy, increasing awareness of advanced methods and technology |
Future Opportunities | Product demand and uptake are increasing due to improved healthcare infrastructure and favorable reimbursement policies for this therapy. |
Market Trends | Rising awareness and expanding market participants venturing into orphan disease management are driving market expansion. |
The key risk factors for acute kidney damage include diabetes, hypertension, and an aging population. Diabetes is becoming increasingly common over the world. As a result, as the prevalence of diabetes rises, so does the count of patients suffering from acute renal injury. Increased knowledge among healthcare providers may lessen its occurrence and enhance the management of the underlying disorders in the elderly population.
As the global incidence of AKI and AKF rises, the demand for continuous renal replacement therapy is predicted to rise. According to the International Society of Nephrology (INR), 13.3 million cases of AKI are reported worldwide each year. This is expected to accelerate the use of continuous renal replacement treatment. The prevalence of kidney-related illnesses is expected to skyrocket as the world's old population expands. This, in turn, is likely to drive significant expansion in the continuous renal replacement treatment market throughout the forecast period.
If left untreated, this condition can cause renal failure or kidney damage. As well as end-stage renal disease, increasing demand for renal replacement treatment. As a result, the rising prevalence of acute and chronic renal illnesses is expected to drive market growth.
Leading industry companies, including Baxter International Inc., Fresenius Kabi, and Medtronic, are investing in Research and development activities. Aiming to develop CRRT systems in order to effect corporate growth. Baxter, for example, has created the PRISMAFLEX critical care system. The PRISMAFLEX system is a versatile platform that provides tailored therapies based on the patient's comfort and suitability. The equipment is outfitted with cutting-edge technology that allows for precise CRRT in patients with acute renal damage.
Furthermore, B. Braun's Diapact CRRT system is integrated with sophisticated technology. It allows the successful treatment of acute kidney injuries and disorders. The crucial blood filtering process is carried out precisely and without interruption, ensuring that patients recover quickly. Such advancements in CRRT systems, together with innovation, result in increased adoption of CRRT systems.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The populace in developing countries is price-sensitive, they favor lower-cost products. Although the cost of continuous renal replacement therapy in developing nations is high-priced. Therefore, a huge percentage of the population cannot afford it due to poor purchasing power. This reduces the demand for the adoption of continuous renal replacement therapy in both developing and developed countries.
Continuous renal replacement therapy (CRRT) is a highly sophisticated and important therapy that necessitates extensive nursing care. Continuous assessment of indications, vascular access, minimizing unnecessary interruptions, and limiting problems all require properly educated ICU nurses. Although, the shortage of licensed nurses in ICU settings may further stymie market expansion.
Companies that manufacture continuous renal replacement treatment products in North America face many regulatory impediments. As a result, the FDA's complicated requirements, reduce demand for these goods. In Europe, for example, CRRT is allowed for a variety of indications. This includes cardiac failure, liver support, intoxication, increased Intracranial Pressure (ICP), rhabdomyolysis, and post-cardiac surgery.
In North America, no CRRT machine has been approved by the FDA for the treatment of several diseases. Similarly, no anticoagulant drug for blood infusion during a CRRT operation has been approved by the FDA so far, despite being licensed in Europe.
Several CRRT drugs that have been approved in other countries have yet to be approved by the FDA in North America due to these stringent regulatory restrictions. The presence of tight regulatory standards for the approval of new CRRT product launches in this region is impeding market growth.
Rising demand for CRRT treatments, radical innovation in systems, and rising frequency of renal disorders are propelling this market in North America.
Emerging markets such as China, India, Brazil, and Mexico are likely to provide considerable growth potential for the market participants. AKI was observed in 17.3 cases per 1,000 individuals in India. According to a study conducted on 100 critically sick patients in a prospective observational study published in the Journal of Clinical and Diagnostic Research (JCDR) 2018. To capitalize on the considerable growth potential in emerging markets, firms are increasingly focused on strategic developments. To enhance their presence in these markets and allow them to reach many clients.
Because of the increased demand from AKI patients, key players in the CRRT market are focusing on creating novel product lines. These firms are working hard to provide low-cost CRRT systems in the Asian market. According to the WHO, renal dialysis is generally available in 60% of nations globally.
Furthermore, due to less onerous data requirements, regulatory rules in the Asia Pacific area are more adaptable and business-friendly. This, combined with increased competition in developed countries (Europe, Japan, and Australia), drives manufacturers of continuous renal replacement treatment products to concentrate on emerging regions.
CRRT consumables include hemofilter, line sets, fluid/dialysate, and accessories. Haemofilters, often known as artificial kidneys, are made of a hollow fiber membrane that controls the amount of solute and fluid evacuated. Businesses such as Baxter and Fresenius offer a variety of consumables across modalities for patients with severe renal diseases. Despite their low cost, these products are more frequently purchased than those in other segments. As a result, the consumables segment is expected to grow at an 8.9% annual rate.
The continuous renal replacement treatment market has been divided by end users into hospitals, clinics, and others. The hospital segment dominated the market in 2018 and continues to do so over the forecast period. The growth in critically sick patients around the world is leading to an increase in patient admissions to ICUs in hospitals. Furthermore, an increase in hospitals worldwide is predicted to help the segment's growth. Top-tier facilities with continuous renal replacement therapy systems in ICUs around the world drive the segment.
In addition, patient preference for hospitals is propelling the segment. In emerging economies, the existence of many hospitals, well-equipped infrastructure, the use of technologically advanced products, and favorable healthcare insurance policies are expected to drive the segment during the projection period.
The market report's competition section includes profiles of prominent market players based on their market shares and product offerings. Similarly, it includes distinct channel strategies, marketing initiatives, product reach, and corporate dashboards.
It is reported to be 93% available in high-income countries, whereas 46% and 27% are available in developing and under-developed countries, respectively. Fresenius Medical Care AG & Co. KGaA, one of the world's top dialysis product and service suppliers, has introduced multi-Filtrate PRO, a Continuous Renal Replacement Therapy (CRRT) therapy system for the treatment of acute kidney failure in critically ill intensive care patients.
To expand their product reach in the Asian market, some leading producers of continuous renal replacement treatment are focused on unique marketing methods. Leading suppliers' price reduction strategy in consumables is a key success factor. These businesses face stiff competition from local consumables providers. These supplies have a firm grip on traditional distribution channels including wholesalers and retailers.
Attribute | Details |
---|---|
Market Size Value in 2023 | US$ 1,214.6 billion |
Market Size Value at End of Forecast (2033) | US$ 2,771.6 billion |
Market Analysis | US$ billion for Value |
Key Region Covered |
|
Key Segments |
|
Key Companies Profiled |
|
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The continuous renal replacement therapy market is anticipated to go up from US$ 1,214.6 billion in 2023 to US$ 2,771.6 billion by 2033, exhibiting a CAGR of 8.6%.
With an 8.3% CAGR between 2018 and 2022, the continuous renal replacement therapy market reached US$ 1,127.0 billion in 2022.
Given its advanced healthcare infrastructure, The United States holds a leading position in the continuous renal replacement therapy market.
Key continuous renal replacement therapy market trends include a surge in home-based therapies and a heightened focus on personalized patient management.
Prominent market players such as Baxter International Inc., B. Braun Melsungen AG, Medica SpA, Nikkiso Co., Ltd., and Nipro Corp. dominate the continuous renal replacement therapy market.
1. Executive Summary | Continuous Renal Replacement Therapy Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Modality 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Modality, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Modality, 2023 to 2033 5.3.1. Slow Continuous Ultrafiltration (SCUF) 5.3.2. Continuous Venovenous Hemofiltration (CVVHF) 5.3.3. Continuous Venovenous Hemodialysis (CVVHD) 5.3.4. Continuous Venovenous Hemodiafiltration (CVVHDF) 5.4. Y-o-Y Growth Trend Analysis By Modality, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Modality, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033 6.3.1. Dialysate & Replacement Fluids 6.3.2. Disposables 6.3.3. Systems 6.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033 7.3.1. Renal 7.3.2. Non-renal 7.3.3. Combination 7.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Modality 9.2.3. By Product 9.2.4. By Therapy 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Modality 9.3.3. By Product 9.3.4. By Therapy 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Modality 10.2.3. By Product 10.2.4. By Therapy 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Modality 10.3.3. By Product 10.3.4. By Therapy 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Modality 11.2.3. By Product 11.2.4. By Therapy 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Modality 11.3.3. By Product 11.3.4. By Therapy 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Modality 12.2.3. By Product 12.2.4. By Therapy 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Modality 12.3.3. By Product 12.3.4. By Therapy 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Modality 13.2.3. By Product 13.2.4. By Therapy 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Modality 13.3.3. By Product 13.3.4. By Therapy 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Modality 14.2.3. By Product 14.2.4. By Therapy 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Modality 14.3.3. By Product 14.3.4. By Therapy 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Modality 15.2.3. By Product 15.2.4. By Therapy 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Modality 15.3.3. By Product 15.3.4. By Therapy 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Modality 16.1.2.2. By Product 16.1.2.3. By Therapy 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Modality 16.2.2.2. By Product 16.2.2.3. By Therapy 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Modality 16.3.2.2. By Product 16.3.2.3. By Therapy 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Modality 16.4.2.2. By Product 16.4.2.3. By Therapy 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Modality 16.5.2.2. By Product 16.5.2.3. By Therapy 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Modality 16.6.2.2. By Product 16.6.2.3. By Therapy 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Modality 16.7.2.2. By Product 16.7.2.3. By Therapy 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Modality 16.8.2.2. By Product 16.8.2.3. By Therapy 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Modality 16.9.2.2. By Product 16.9.2.3. By Therapy 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Modality 16.10.2.2. By Product 16.10.2.3. By Therapy 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Modality 16.11.2.2. By Product 16.11.2.3. By Therapy 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Modality 16.12.2.2. By Product 16.12.2.3. By Therapy 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Modality 16.13.2.2. By Product 16.13.2.3. By Therapy 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Modality 16.14.2.2. By Product 16.14.2.3. By Therapy 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Modality 16.15.2.2. By Product 16.15.2.3. By Therapy 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Modality 16.16.2.2. By Product 16.16.2.3. By Therapy 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Modality 16.17.2.2. By Product 16.17.2.3. By Therapy 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Modality 16.18.2.2. By Product 16.18.2.3. By Therapy 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Modality 16.19.2.2. By Product 16.19.2.3. By Therapy 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Modality 16.20.2.2. By Product 16.20.2.3. By Therapy 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Modality 16.21.2.2. By Product 16.21.2.3. By Therapy 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Modality 17.3.3. By Product 17.3.4. By Therapy 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. B. Braun Melsungen AG 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Baxter International, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Fresenius Medical Care AG & Co. KGaA 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Asahi Kasei Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. NIPRO Corporation 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Toray Medical Co., Ltd 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. NxStage Medical, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Medtronic plc 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Abbott 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Pfizer 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Modality, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Product, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Modality, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Product, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 17: Global Market Attractiveness by Modality, 2023 to 2033 Figure 18: Global Market Attractiveness by Product, 2023 to 2033 Figure 19: Global Market Attractiveness by Therapy, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Modality, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Product, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 37: North America Market Attractiveness by Modality, 2023 to 2033 Figure 38: North America Market Attractiveness by Product, 2023 to 2033 Figure 39: North America Market Attractiveness by Therapy, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Modality, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Product, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Modality, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Product, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Therapy, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Modality, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Product, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 77: Europe Market Attractiveness by Modality, 2023 to 2033 Figure 78: Europe Market Attractiveness by Product, 2023 to 2033 Figure 79: Europe Market Attractiveness by Therapy, 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Modality, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by Product, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 97: South Asia Market Attractiveness by Modality, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Product, 2023 to 2033 Figure 99: South Asia Market Attractiveness by Therapy, 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Modality, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by Product, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 117: East Asia Market Attractiveness by Modality, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Product, 2023 to 2033 Figure 119: East Asia Market Attractiveness by Therapy, 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Modality, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by Product, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 137: Oceania Market Attractiveness by Modality, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Product, 2023 to 2033 Figure 139: Oceania Market Attractiveness by Therapy, 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Modality, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Product, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Modality, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Modality, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Modality, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Product, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Product, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 157: MEA Market Attractiveness by Modality, 2023 to 2033 Figure 158: MEA Market Attractiveness by Product, 2023 to 2033 Figure 159: MEA Market Attractiveness by Therapy, 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports